EwaMrozekMD

Oncology • London, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Mrozek is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mrozek's full profile

Already have an account?

Office
210 N Main St
London, OH 43140
Phone+1 740-845-7518

Fax+1 740-845-7701

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
New York-Presbyterian Brooklyn Methodist HospitalResidency, Internal Medicine, 1996 - 1999
Gdański Uniwersytet MedycznyClass of 1983

Certifications & Licensure

OH State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 2
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer Start of enrollment: 2010 Dec 01
Terminated
Phase 1
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery Start of enrollment: 2017 Feb 16
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2025-02-01
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, Ashley Pinette, Brooke Benner
Cancer Control. 2024-05-27
9 citations
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine P...
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao
The Oncologist. 2020-08-01

Press Mentions

Fitness More Important Than Age in Choosing Treatment for DiseaseDecember 27th, 2015